Kelley Burridge PhD U.S. FDA
Dr. Kelley Burridge currently serves as a product quality team leader in the Office of Pharmaceutical Quality (OPQ) in the Center for Drug Evaluation and Research (CDER) at the US FDA. She leads a team of reviewers in the assessment of chemistry, manufacturing, and controls (CMC) information for pre- and post-market human therapeutic biologic drugs. Dr. Burridge is a member of the OPQ Emerging Technology Team.
Previous FDA positions include a chemistry reviewer in the Office of Life-cycle Drug Products (2014-2019) and lead reviewer of plastic and reconstructive surgery devices in the Center for Devices and Radiological Health (CDRH, 2010-2014). Prior to joining the FDA, she obtained postdoctoral training experience and worked as an industrial process engineer. Dr. Burridge received a BS in Chemical Engineering from Cornell University and a PhD in Biomedical Engineering from Boston University with special training in Biomolecular Pharmacology.
Previous FDA positions include a chemistry reviewer in the Office of Life-cycle Drug Products (2014-2019) and lead reviewer of plastic and reconstructive surgery devices in the Center for Devices and Radiological Health (CDRH, 2010-2014). Prior to joining the FDA, she obtained postdoctoral training experience and worked as an industrial process engineer. Dr. Burridge received a BS in Chemical Engineering from Cornell University and a PhD in Biomedical Engineering from Boston University with special training in Biomolecular Pharmacology.